Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 8/20 | 0.59 |
| ▸ | EBP | Q15125 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | MPO | P05164 | 1/20 | 0.43 |
| ▸ | CYP27A1 | Q02318 | 2/20 | 0.42 |
| ▸ | CYP24A1 | Q07973 | 2/20 | 0.42 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.41 |
| ▸ | NQO2 | P16083 | 1/20 | 0.41 |
| ▸ | MIF | P14174 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3849269 | 0.93 | ESR1 (0.57) | ESR1EBPSIGMAR1ACHEMPO | |
| SCHEMBL3847255 | 0.92 | ESR1 (0.52) | ESR1EBPSIGMAR1MPOCYP19A1 | |
| SCHEMBL3852865 | 0.90 | ESR1 (0.61) | ESR1EBPSIGMAR1ACHEMPO | |
| SCHEMBL3651345 | 0.88 | ESR1 (0.63) | ESR1MPOCYP24A1MIF | |
| SCHEMBL15028516 | 0.85 | ESR1 (0.56) | ESR1EBPSIGMAR1ACHECYP27A1 | |
| SCHEMBL15028579 | 0.85 | ESR1 (0.56) | ESR1EBPSIGMAR1ACHECYP27A1 | |
| SCHEMBL3657949 | 0.83 | ESR1 (0.63) | ESR1MIFMAOAMAOB | |
| SCHEMBL3653454 | 0.82 | ESR1 (0.58) | ESR1MAOAMAOB | |
| SCHEMBL3653309 | 0.82 | ESR1 (0.54) | ESR1EBPSIGMAR1MPOCYP19A1 | |
| SCHEMBL3650114 | 0.81 | ESR1 (0.54) | ESR1EBPSIGMAR1ACHECYP24A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099250-A1 | BENZOCYCLOHEPTENE DERIVATIVES AS ESTROGENS HAVING SELECTIVE ACTIVITY | BAYER SCHERING PHARMA AG (DE) | 2009-04-16 | — | — | US | claimed |
| EP-2048126-A1 | Benzocycloheptane derivatives as selectively active oestrogens | Bayer Schering Pharma AG (DE) | 2009-04-15 | — | — | EP | claimed |
| US-20090099250-A1 | BENZOCYCLOHEPTENE DERIVATIVES AS ESTROGENS HAVING SELECTIVE ACTIVITY | BAYER SCHERING PHARMA AG (DE) | 2009-04-16 | — | — | US | disclosed |
| EP-2048126-A1 | Benzocycloheptane derivatives as selectively active oestrogens | Bayer Schering Pharma AG (DE) | 2009-04-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099250-A1 | BENZOCYCLOHEPTENE DERIVATIVES AS ESTROGENS HAVING SELECTIVE ACTIVITY | CYP19A1, HSD17B11, CYP21A2 | ESR1 4/4885EBP 99/4885SIGMAR1 330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.